Trimetazidine - Martin Pharmaceuticals

Drug Profile

Trimetazidine - Martin Pharmaceuticals

Alternative Names: LIVANTRA

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Martin Pharmaceuticals
  • Class Anti-ischaemics; Ischaemic heart disorder therapies; Piperazines; Small molecules; Vasodilators
  • Mechanism of Action Adenosine triphosphatase inhibitors; Calcium channel antagonists; Free radical scavengers; Platelet aggregation inhibitors; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Liver failure

Most Recent Events

  • 29 Mar 2018 Research programme : therapeutics - Martin Pharmaceuticals receives Orphan Drug status for Liver failure in USA
  • 15 Mar 2018 Preclinical trials in Liver failure in USA (unspecified route)
  • 15 Mar 2018 Martin Therapeutics plans a phase I/IIa trial in unknown indication
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top